{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:17:23Z","timestamp":1788398243822,"version":"build-2803163510"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministerio de Ciencia e Innovaci\u00f3n and the Spanish Research Agency"},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP20\/00003"],"award-info":[{"award-number":["CP20\/00003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00297"],"award-info":[{"award-number":["PI22\/00297"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA116623"],"award-info":[{"award-number":["R01 CA116623"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC151072"],"award-info":[{"award-number":["BC151072"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC151072P1"],"award-info":[{"award-number":["BC151072P1"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapy-induced senescence (TIS) in cancer cells can be triggered by radiotherapy, chemotherapy, and certain targeted therapeutics. Here, we demonstrate that a new form of TIS, termed fatty acid synthesis therapy-induced senescence (FASTIS), can be induced by pharmacologically targeting de novo lipogenesis. Cancer cells can evade the anti-proliferative effects of clinically relevant inhibitors of core lipogenic enzymes, such as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN), by entering in a senescence-like state. FASTIS cancer cells acquire the classical senescence hallmarks, such as cytomorphological remodeling, increased senescence-associated beta-galatosidase (SA-\u03b2-gal) activity, activation of cell cycle arrest markers, and hypersensitivity to IFN\u03b3-induced activation of the immune checkpoint PD-L1. mRNA sequencing reveals an FASTIS-associated transcriptomic profile that overlaps between ACC and FASN inhibitors yet differs significantly from that of other mechanistically diverse TIS inducers, including bleomycin, alisertib, doxorubicin, and palbociclib. The FASTIS-encoding transcriptome is characterized by the activation of cholesterol- and acetyl-CoA-related lipogenic pathways, as well as cell-intrinsic innate immune responses. This profile is characterized as highly senescent (\u22650.95) by the machine learning\u2013based senescence predictor SENCAN. Mapping the metabolome and lipidome in FASTIS cells reveals a significant sterol lipid enrichment, including substantial increases in intracellular cholesterol levels. Pharmacological blockade of cholesterol synthesis or promotion of lysosomal cholesterol accumulation, prevents or potentiates the occurrence of SA-\u03b2-gal+ FASTIS cells, respectively. Cytokine arrays and miR-146a reporter-based screens revealed that the FASTIS-associated secretory phenotype (FASASP) is highly enriched in immunomodulatory factors but not in inflammatory components. FASTIS cancer cells exhibit an increased overall level of mitochondrial priming, making them highly susceptible to targeted senolysis by BCL-xL-targeting BH3 mimetics and cytokine-activated T cells. The FASTIS phenomenon is a therapeutic outcome through which cancer cells adapt to survive clinical-grade lipogenesis inhibitors. The cholesterol-addicted FASTIS fate can be rationally exploited as a collateral sensitivity in \u201cone-two punch\u201d senogenic-(immuno)senolytic strategies.<\/jats:p>","DOI":"10.1038\/s41419-026-08992-8","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:57:20Z","timestamp":1781719040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cells"],"prefix":"10.1038","volume":"17","author":[{"given":"Sara","family":"Verdura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0ngela","family":"Llop-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Van der Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Encinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Martin-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5353-440X","authenticated-orcid":false,"given":"Elisabet","family":"Cuy\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-3172","authenticated-orcid":false,"given":"Ruth","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-4561","authenticated-orcid":false,"given":"Javier A.","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"8992_CR1","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrm3823","volume":"15","author":"D Mu\u00f1oz-Esp\u00edn","year":"2014","unstructured":"Mu\u00f1oz-Esp\u00edn D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15:482\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8992_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2159-8290.CD-22-0523","volume":"13","author":"I Marin","year":"2023","unstructured":"Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, et al. Cellular senescence is immunogenic and promotes antitumor immunity. Cancer Discov. 2023;13:410\u201331.","journal-title":"Cancer Discov"},{"key":"8992_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-22-0528","volume":"13","author":"HA Chen","year":"2023","unstructured":"Chen HA, Ho YJ, Mezzadra R, Adrover JM, Smolkin R, Zhu C, et al. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 2023;13:432\u201353.","journal-title":"Cancer Discov"},{"key":"8992_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-cancerbio-061421-124434","volume":"7","author":"PB Romesser","year":"2023","unstructured":"Romesser PB, Lowe SW. The potent and paradoxical biology of cellular senescence in cancer. Annu Rev Cancer Biol. 2023;7:207\u201328.","journal-title":"Annu Rev Cancer Biol"},{"key":"8992_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8992_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/path.6164","volume":"260","author":"K Evangelou","year":"2023","unstructured":"Evangelou K, Belogiannis K, Papaspyropoulos A, Petty R, Gorgoulis VG. Escape from senescence: molecular basis and therapeutic ramifications. J Pathol. 2023;260:649\u201365.","journal-title":"J Pathol"},{"key":"8992_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10522-015-9593-9","volume":"17","author":"LC Gonzalez","year":"2016","unstructured":"Gonzalez LC, Ghadaouia S, Martinez A, Rodier F. Premature aging\/senescence in cancer cells facing therapy: good or bad? Biogerontology. 2016;17:71\u201387.","journal-title":"Biogerontology"},{"key":"8992_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.trecan.2020.05.004","volume":"6","author":"B Wang","year":"2020","unstructured":"Wang B, Kohli J, Demaria M. Senescent cells in cancer therapy: friends or foes? Trends Cancer. 2020;6:838\u201357.","journal-title":"Trends Cancer"},{"key":"8992_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jnci\/djab064","volume":"113","author":"PG Prasanna","year":"2021","unstructured":"Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, et al. Therapy-induced senescence: opportunities to improve anticancer therapy. J Natl Cancer Inst. 2021;113:1285\u201398.","journal-title":"J Natl Cancer Inst"},{"key":"8992_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria M, O\u2019Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7:165\u201376.","journal-title":"Cancer Discov"},{"key":"8992_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/jnci\/djaa060","volume":"113","author":"JL Guida","year":"2021","unstructured":"Guida JL, Agurs-Collins T, Ahles TA, Campisi J, Dale W, Demark-Wahnefried W, et al. Strategies to prevent or remediate cancer and treatment-related aging. J Natl Cancer Inst. 2021;113:112\u201322.","journal-title":"J Natl Cancer Inst"},{"key":"8992_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.canlet.2021.07.002","volume":"520","author":"JW Zhang","year":"2021","unstructured":"Zhang JW, Zhang D, Yu BP. Senescent cells in cancer therapy: why and how to remove them. Cancer Lett. 2021;520:68\u201379.","journal-title":"Cancer Lett"},{"key":"8992_CR13","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1002\/1878-0261.13312","volume":"16","author":"L Bousset","year":"2022","unstructured":"Bousset L, Gil J. Targeting senescence as an anticancer therapy. Mol Oncol. 2022;16:3855\u201380.","journal-title":"Mol Oncol"},{"key":"8992_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41420-020-0286-z","volume":"6","author":"MM Faheem","year":"2020","unstructured":"Faheem MM, Seligson ND, Ahmad SM, Rasool RU, Gandhi SG, Bhagat M, et al. Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives. Cell Death Discov. 2020;6:51.","journal-title":"Cell Death Discov"},{"key":"8992_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s42003-021-02257-0","volume":"4","author":"K Santos-de-Frutos","year":"2021","unstructured":"Santos-de-Frutos K, Djouder N. When dormancy fuels tumour relapse. Commun Biol. 2021;4:747.","journal-title":"Commun Biol"},{"key":"8992_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.semcancer.2022.02.005","volume":"86","author":"L Chibaya","year":"2022","unstructured":"Chibaya L, Snyder J, Ruscetti M. Senescence and the tumor-immune landscape: Implications for cancer immunotherapy. Semin Cancer Biol. 2022;86:827\u201345.","journal-title":"Semin Cancer Biol"},{"key":"8992_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/1878-0261.13541","volume":"18","author":"DH Lee","year":"2024","unstructured":"Lee DH, Imran M, Choi JH, Park YJ, Kim YH, Min S, et al. CDK4\/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents. Mol Oncol. 2024;18:216\u201332.","journal-title":"Mol Oncol"},{"key":"8992_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.celrep.2017.09.085","volume":"21","author":"L Wang","year":"2017","unstructured":"Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, et al. High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer. Cell Rep. 2017;21:773\u201383.","journal-title":"Cell Rep"},{"key":"8992_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11684-018-0647-7","volume":"12","author":"L Wang","year":"2018","unstructured":"Wang L, Bernards R. Taking advantage of drug resistance, a new approach in the war on cancer. Front Med. 2018;12:490\u20135.","journal-title":"Front Med"},{"key":"8992_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","volume":"19","author":"CA Schmitt","year":"2022","unstructured":"Schmitt CA, Wang B, Demaria M. Senescence and cancer - role and therapeutic opportunities. Nat Rev Clin Oncol. 2022;19:619\u201336.","journal-title":"Nat Rev Clin Oncol"},{"key":"8992_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355.","journal-title":"Nat Rev Cancer"},{"key":"8992_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41418-024-01439-7","volume":"32","author":"F Jochems","year":"2025","unstructured":"Jochems F, Baltira C, MacDonald JA, Daniels V, Mathur A, de Gooijer MC, et al. Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. Cell Death Differ. 2025;32:855\u201365.","journal-title":"Cell Death Differ"},{"key":"8992_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41418-024-01431-1","volume":"32","author":"JA MacDonald","year":"2025","unstructured":"MacDonald JA, Bradshaw GA, Jochems F, Bernards R, Letai A. Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies. Cell Death Differ. 2025;32:802\u201317.","journal-title":"Cell Death Differ"},{"key":"8992_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41420-025-02379-y","volume":"11","author":"J L\u00f3pez","year":"2025","unstructured":"L\u00f3pez J, Verdura S, Llop-Hern\u00e1ndez \u00c0, Serrano-Herv\u00e1s E, Mart\u00ednez-Balivrea E, Bosch-Barrera J, et al. Mitochondrial priming and response to BH3 mimetics in \u201cone-two punch\u201d senogenic-senolytic strategies. Cell Death Discov. 2025;11:91.","journal-title":"Cell Death Discov"},{"key":"8992_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41420-026-02967-6","volume":"12","author":"\u00c0 Llop-Hern\u00e1ndez","year":"2026","unstructured":"Llop-Hern\u00e1ndez \u00c0, Verdura S, L\u00f3pez J, Martin-Castillo B, Menendez JA, Cuy\u00e0s E. Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence. Cell Death Discov. 2026;12:103.","journal-title":"Cell Death Discov"},{"key":"8992_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1695244","volume":"16","author":"JA Menendez","year":"2025","unstructured":"Menendez JA, Lupu R, Martin-Castillo B, Sardany\u00e9s J, Alarc\u00f3n T, Verdura S, et al. Mitochondrial priming in therapy-induced senescence: implications for CAR-T\/NK immunosenolytic therapy. Front Immunol. 2025;16:1695244.","journal-title":"Front Immunol"},{"key":"8992_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"8992_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21:297\u2013308.","journal-title":"Cancer Cell"},{"key":"8992_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"8992_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355\u201377.","journal-title":"Cell Metab"},{"key":"8992_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"8992_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148550","volume":"132","author":"KM Lemberg","year":"2022","unstructured":"Lemberg KM, Gori SS, Tsukamoto T, Rais R, Slusher BS. Clinical development of metabolic inhibitors for oncology. J Clin Invest. 2022;132:e148550.","journal-title":"J Clin Invest"},{"key":"8992_CR33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763\u201377.","journal-title":"Nat Rev Cancer"},{"key":"8992_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4\u201322.","journal-title":"Br J Cancer"},{"key":"8992_CR35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732\u201349.","journal-title":"Nat Rev Cancer"},{"key":"8992_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-023-00460-8","volume":"12","author":"D Vanauberg","year":"2023","unstructured":"Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. Oncogenesis. 2023;12:16.","journal-title":"Oncogenesis"},{"key":"8992_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/1878-0261.13582","volume":"18","author":"JA Menendez","year":"2024","unstructured":"Menendez JA, Cuy\u00e0s E, Encinar JA, Vander Steen T, Verdura S, Llop-Hern\u00e1ndez \u00c0, et al. Fatty acid synthase (FASN) signalome: a molecular guide for precision oncology. Mol Oncol. 2024;18:479\u2013516.","journal-title":"Mol Oncol"},{"key":"8992_CR38","doi-asserted-by":"publisher","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","volume":"113","author":"G Harriman","year":"2016","unstructured":"Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci USA. 2016;113:E1796\u2013805.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8992_CR39","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nm.4181","volume":"22","author":"RU Svensson","year":"2016","unstructured":"Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016;22:1108\u201319.","journal-title":"Nat Med"},{"key":"8992_CR40","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1021\/acs.jmedchem.7b01547","volume":"61","author":"R Mizojiri","year":"2018","unstructured":"Mizojiri R, Asano M, Tomita D, Banno H, Nii N, Sasaki M, et al. Discovery of novel selective acetyl-CoA Carboxylase (ACC) 1 Inhibitors. J Med Chem. 2018;61:1098\u2013117.","journal-title":"J Med Chem"},{"key":"8992_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105010","volume":"137","author":"EQ Li","year":"2019","unstructured":"Li EQ, Zhao W, Zhang C, Qin LZ, Liu SJ, Feng ZQ, et al. Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors. Eur J Pharm Sci. 2019;137:105010.","journal-title":"Eur J Pharm Sci"},{"key":"8992_CR42","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ebiom.2015.06.020","volume":"2","author":"R Ventura","year":"2015","unstructured":"Ventura R, Mordec K, Waszczuk J, Wang Z, Lai J, Fridlib M, et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression. EBioMedicine. 2015;2:808\u201324.","journal-title":"EBioMedicine"},{"key":"8992_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ebiom.2016.12.012","volume":"16","author":"TS Heuer","year":"2017","unstructured":"Heuer TS, Ventura R, Mordec K, Lai J, Fridlib M, Buckley D, et al. FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression. EBioMedicine. 2017;16:51\u201362.","journal-title":"EBioMedicine"},{"key":"8992_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797.","journal-title":"EClinicalMedicine"},{"key":"8992_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101143","volume":"62","author":"TV Steen","year":"2025","unstructured":"Steen TV, Espinoza I, Duran C, Casadevall G, Serrano-Herv\u00e1s E, Cuy\u00e0s E, et al. Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer. Neoplasia. 2025;62:101143.","journal-title":"Neoplasia"},{"key":"8992_CR46","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1073\/pnas.91.14.6379","volume":"91","author":"FP Kuhajda","year":"1994","unstructured":"Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 1994;91:6379\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8992_CR47","doi-asserted-by":"publisher","first-page":"26122","DOI":"10.1074\/jbc.M702854200","volume":"282","author":"S Yoon","year":"2007","unstructured":"Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem. 2007;282:26122\u201331.","journal-title":"J Biol Chem"},{"key":"8992_CR48","doi-asserted-by":"publisher","first-page":"e97697","DOI":"10.1371\/journal.pone.0097697","volume":"9","author":"C Yan","year":"2014","unstructured":"Yan C, Wei H, Minjuan Z, Yan X, Jingyue Y, Wenchao L, et al. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER\/HER2-positive breast cancer cells. PLoS One. 2014;9:e97697.","journal-title":"PLoS One"},{"key":"8992_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04262-x","volume":"12","author":"B Schroeder","year":"2021","unstructured":"Schroeder B, Vander Steen T, Espinoza I, Venkatapoorna CMK, Hu Z, Silva FM, et al. Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death Dis. 2021;12:977.","journal-title":"Cell Death Dis"},{"key":"8992_CR50","doi-asserted-by":"publisher","first-page":"8180","DOI":"10.1158\/0008-5472.CAN-07-0389","volume":"67","author":"A Beckers","year":"2007","unstructured":"Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 2007;67:8180\u20137.","journal-title":"Cancer Res"},{"key":"8992_CR51","doi-asserted-by":"publisher","first-page":"8306","DOI":"10.18632\/oncotarget.2059","volume":"5","author":"B Corominas-Faja","year":"2014","unstructured":"Corominas-Faja B, Cuy\u00e0s E, Gumuzio J, Bosch-Barrera J, Leis O, Martin \u00c1G, et al. Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget. 2014;5:8306\u201316.","journal-title":"Oncotarget"},{"key":"8992_CR52","first-page":"687","volume":"32","author":"B Corominas-Faja","year":"2017","unstructured":"Corominas-Faja B, Vellon L, Cuy\u00e0s E, Bux\u00f3 M, Martin-Castillo B, Serra D, et al. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histol Histopathol. 2017;32:687\u201398.","journal-title":"Histol Histopathol"},{"key":"8992_CR53","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108946","volume":"41","author":"B Wang","year":"2022","unstructured":"Wang B, Varela-Eirin M, Brandenburg SM, Hernandez-Segura A, van Vliet T, Jongbloed EM, et al. Pharmacological CDK4\/6 inhibition reveals a p53-dependent senescent state with restricted toxicity. EMBO J. 2022;41:e108946.","journal-title":"EMBO J"},{"key":"8992_CR54","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108599","volume":"41","author":"L Crozier","year":"2022","unstructured":"Crozier L, Foy R, Mouery BL, Whitaker RH, Corno A, Spanos C, et al. CDK4\/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal. EMBO J. 2022;41:e108599.","journal-title":"EMBO J"},{"key":"8992_CR55","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1016\/j.molcel.2023.10.016","volume":"83","author":"L Crozier","year":"2023","unstructured":"Crozier L, Foy R, Adib R, Kar A, Holt JA, Pareri AU, et al. CDK4\/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence. Mol Cell. 2023;83:4062\u201377.","journal-title":"Mol Cell"},{"key":"8992_CR56","doi-asserted-by":"publisher","first-page":"10715","DOI":"10.1073\/pnas.0403390101","volume":"101","author":"JA Menendez","year":"2004","unstructured":"Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2\/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA. 2004;101:10715\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8992_CR57","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/mc.20054","volume":"41","author":"JA Menendez","year":"2004","unstructured":"Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2\/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog. 2004;41:164\u201378.","journal-title":"Mol Carcinog"},{"key":"8992_CR58","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","volume":"28","author":"A Hernandez-Segura","year":"2018","unstructured":"Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 2018;28:436\u201353.","journal-title":"Trends Cell Biol"},{"key":"8992_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular senescence: defining a path forward. Cell. 2019;179:813\u201327.","journal-title":"Cell"},{"key":"8992_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/febs.15570","volume":"288","author":"E Gonz\u00e1lez-Gualda","year":"2021","unstructured":"Gonz\u00e1lez-Gualda E, Baker AG, Fruk L, Mu\u00f1oz-Esp\u00edn D. A guide to assessing cellular senescence in vitro and in vivo. FEBS J. 2021;288:56\u201380.","journal-title":"FEBS J"},{"key":"8992_CR61","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.molcel.2004.11.034","volume":"16","author":"Y Shen","year":"2004","unstructured":"Shen Y, Volrath SL, Weatherly SC, Elich TD, Tong L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol Cell. 2004;16:881\u201391.","journal-title":"Mol Cell"},{"key":"8992_CR62","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bbrc.2009.11.029","volume":"391","author":"YS Cho","year":"2010","unstructured":"Cho YS, Lee JI, Shin D, Kim HT, Jung HY, Lee TG, et al. Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK. Biochem Biophys Res Commun. 2010;391:187\u201392.","journal-title":"Biochem Biophys Res Commun"},{"key":"8992_CR63","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1073\/pnas.97.7.3450","volume":"97","author":"FP Kuhajda","year":"2000","unstructured":"Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA. 2000;97:3450\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8992_CR64","doi-asserted-by":"publisher","first-page":"11355","DOI":"10.1096\/fj.202000705R","volume":"34","author":"N Montesdeoca","year":"2020","unstructured":"Montesdeoca N, L\u00f3pez M, Ariza X, Herrero L, Makowski K. Inhibitors of lipogenic enzymes as a potential therapy against cancer. FASEB J. 2020;34:11355\u201381.","journal-title":"FASEB J"},{"key":"8992_CR65","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s43018-022-00466-y","volume":"3","author":"A Shahbandi","year":"2022","unstructured":"Shahbandi A, Chiu FY, Ungerleider NA, Kvadas R, Mheidly Z, Sun MJS, et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat Cancer. 2022;3:1513\u201333.","journal-title":"Nat Cancer"},{"key":"8992_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00171-22","volume":"42","author":"A Onorati","year":"2022","unstructured":"Onorati A, Havas AP, Lin B, Rajagopal J, Sen P, Adams PD, Dou Z. Upregulation of PD-L1 in Senescence and Aging. Mol Cell Biol. 2022;42:e0017122.","journal-title":"Mol Cell Biol"},{"key":"8992_CR67","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41556-024-01465-0","volume":"26","author":"J Majewska","year":"2024","unstructured":"Majewska J, Agrawal A, Mayo A, Roitman L, Chatterjee R, Sekeresova Kralova J, et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat Cell Biol. 2024;26:1336\u201345.","journal-title":"Nat Cell Biol"},{"key":"8992_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54132-1","volume":"16","author":"HJ Hwang","year":"2025","unstructured":"Hwang HJ, Kang D, Shin J, Jung J, Ko S, Jung KH, et al. Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation. Nat Commun. 2025;16:353.","journal-title":"Nat Commun"},{"key":"8992_CR69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic M, Fan DNY, Belenki D, D\u00e4britz JHM, Zhao Z, Yu Y, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96\u2013100.","journal-title":"Nature"},{"key":"8992_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10460-1","volume":"10","author":"H Fleury","year":"2019","unstructured":"Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun. 2019;10:2556.","journal-title":"Nat Commun"},{"key":"8992_CR71","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232136","volume":"221","author":"M Reimann","year":"2024","unstructured":"Reimann M, Lee S, Schmitt CA. Cellular senescence: neither irreversible nor reversible. J Exp Med. 2024;221:e20232136.","journal-title":"J Exp Med"},{"key":"8992_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66836-z","volume":"17","author":"B Fernandez","year":"2025","unstructured":"Fernandez B, Passanisi VJ, Ashraf HM, Spencer SL. Single-cell RNA sequencing reveals a quiescence-senescence continuum and distinct senotypes following chemotherapy. Nat Commun. 2025;17:169.","journal-title":"Nat Commun"},{"key":"8992_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109441","volume":"36","author":"F Jochems","year":"2021","unstructured":"Jochems F, Thijssen B, De Conti G, Jansen R, Pogacar Z, Groot K, et al. The cancer SENESCopedia: a delineation of cancer cell senescence. Cell Rep. 2021;36:109441.","journal-title":"Cell Rep"},{"key":"8992_CR74","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1038\/s41388-022-02433-4","volume":"41","author":"J Morales-Valencia","year":"2022","unstructured":"Morales-Valencia J, Lau L, Mart\u00ed-Nin T, Ozerdem U, David G. Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression. Oncogene. 2022;41:4361\u201370.","journal-title":"Oncogene"},{"key":"8992_CR75","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen J, Melero I, Fridman WH. Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:951.","journal-title":"Front Immunol"},{"key":"8992_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4049\/jimmunol.2200641","volume":"210","author":"J Reyes","year":"2023","unstructured":"Reyes J, Yap GS. Emerging roles of growth differentiation factor 15 in immunoregulation and pathogenesis. J Immunol. 2023;210:5\u201311.","journal-title":"J Immunol"},{"key":"8992_CR77","doi-asserted-by":"publisher","first-page":"e202000809","DOI":"10.26508\/lsa.202000809","volume":"4","author":"N Mullani","year":"2021","unstructured":"Mullani N, Porozhan Y, Mangelinck A, Rachez C, Costallat M, Batsch\u00e9 E, et al. Reduced RNA turnover as a driver of cellular senescence. Life Sci Alliance. 2021;4:e202000809.","journal-title":"Life Sci Alliance"},{"key":"8992_CR78","doi-asserted-by":"publisher","first-page":"22508","DOI":"10.18632\/oncotarget.7999","volume":"7","author":"A Gibadulinova","year":"2016","unstructured":"Gibadulinova A, Pastorek M, Filipcik P, Radvak P, Csaderova L, Vojtesek B, et al. Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance. Oncotarget. 2016;7:22508\u201322.","journal-title":"Oncotarget"},{"key":"8992_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55785-8","volume":"16","author":"M Yang","year":"2025","unstructured":"Yang M, Cui W, Lv X, Xiong G, Sun C, Xuan H, et al. S100P is a ferroptosis suppressor to facilitate hepatocellular carcinoma development by rewiring lipid metabolism. Nat Commun. 2025;16:509.","journal-title":"Nat Commun"},{"key":"8992_CR80","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/2159-8290.CD-13-0287","volume":"4","author":"N Murugaesu","year":"2014","unstructured":"Murugaesu N, Iravani M, van Weverwijk A, Ivetic A, Johnson DA, Antonopoulos A, et al. An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov. 2014;4:304\u201317.","journal-title":"Cancer Discov"},{"key":"8992_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1020-4","volume":"18","author":"M Xu","year":"2019","unstructured":"Xu M, Wang F, Li G, Wang X, Fang X, Jin H, et al. MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2\/cofilin pathway in NSCLC. Mol Cancer. 2019;18:93.","journal-title":"Mol Cancer"},{"key":"8992_CR82","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","volume":"29","author":"JSV Lally","year":"2019","unstructured":"Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, et al. Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29:174\u201382.","journal-title":"Cell Metab"},{"key":"8992_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157438","volume":"148","author":"ZH Deng","year":"2025","unstructured":"Deng ZH, He LJ, Wei S, Li CS, Chen Y, Ai XY, et al. Unveiling plumbagin as a novel metabolic modulator to suppress ACC1-mediated de novo lipogenesis in non-small cell lung cancer. Phytomedicine. 2025;148:157438.","journal-title":"Phytomedicine"},{"key":"8992_CR84","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41420-024-02184-z","volume":"10","author":"E Cuy\u00e0s","year":"2024","unstructured":"Cuy\u00e0s E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Herv\u00e1s E, et al. Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity. Cell Death Discov. 2024;10:417.","journal-title":"Cell Death Discov"},{"key":"8992_CR85","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/B978-0-12-386487-1.00017-1","volume":"108","author":"FR Maxfield","year":"2012","unstructured":"Maxfield FR, W\u00fcstner D. Analysis of cholesterol trafficking with fluorescent probes. Methods Cell Biol. 2012;108:367\u201393.","journal-title":"Methods Cell Biol"},{"key":"8992_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-4318-1_8","volume":"2888","author":"J Eichler","year":"2025","unstructured":"Eichler J, Huver S, Knorr CJ, Wendling C, Kobayashi T, Tomasetto C, et al. Methods for visualizing and quantifying cholesterol distribution in mammalian cells using filipin and D4 probes. Methods Mol Biol. 2025;2888:101\u201318.","journal-title":"Methods Mol Biol"},{"key":"8992_CR87","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2014.12.002","volume":"27","author":"ZT Schug","year":"2015","unstructured":"Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 2015;27:57\u201371.","journal-title":"Cancer Cell"},{"key":"8992_CR88","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/1873-3468.70152","volume":"599","author":"M Gunasekaran","year":"2025","unstructured":"Gunasekaran M, Campos G, Wells NM, Lambuu K, Draper I, Pacak CA, et al. ACSS2 involved in acetyl-CoA synthesis regulates skeletal muscle function. FEBS Lett. 2025;599:2817\u201327.","journal-title":"FEBS Lett"},{"key":"8992_CR89","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1080\/15548627.2019.1586257","volume":"15","author":"G Sharma","year":"2019","unstructured":"Sharma G, Guardia CM, Roy A, Vassilev A, Saric A, Griner LN, et al. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis. Autophagy. 2019;15:1694\u2013718.","journal-title":"Autophagy"},{"key":"8992_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65798-6","volume":"16","author":"C Kutchukian","year":"2025","unstructured":"Kutchukian C, Casas M, Dixon RE, Dickson EJ. Disruption of the PIKfyve complex unveils an adaptive mechanism to promote lysosomal repair and mitochondrial homeostasis. Nat Commun. 2025;16:10761.","journal-title":"Nat Commun"},{"key":"8992_CR91","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/blood.2025030061","volume":"147","author":"C Bonolo de Campos","year":"2026","unstructured":"Bonolo de Campos C, He R, Pelino T, Abelman DD, Li Z, Lee DKC, et al. PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism. Blood. 2026;147:650\u201361.","journal-title":"Blood"},{"key":"8992_CR92","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.molcel.2021.03.018","volume":"81","author":"T van Vliet","year":"2021","unstructured":"van Vliet T, Varela-Eirin M, Wang B, Borghesan M, Brandenburg SM, Franzin R, et al. Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression. Mol Cell. 2021;81:2041\u201352.","journal-title":"Mol Cell"},{"key":"8992_CR93","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang B, Han J, Elisseeff JH, Demaria M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol. 2024;25:958\u201378.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8992_CR94","doi-asserted-by":"publisher","first-page":"402","DOI":"10.18632\/aging.100042","volume":"1","author":"D Bhaumik","year":"2009","unstructured":"Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, et al. MicroRNAs miR-146a\/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY). 2009;1:402\u201311.","journal-title":"Aging (Albany NY)"},{"key":"8992_CR95","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa5612","volume":"349","author":"C Kang","year":"2015","unstructured":"Kang C, Xu Q, Martin TD, Li MZ, Demaria M, Aron L, et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science. 2015;349:aaa5612.","journal-title":"Science"},{"key":"8992_CR96","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41418-024-01417-z","volume":"32","author":"C Alcon","year":"2025","unstructured":"Alcon C, Kovatcheva M, Morales-S\u00e1nchez P, L\u00f3pez-Polo V, Torres T, Puig S, et al. HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells. Cell Death Differ. 2025;32:646\u201356.","journal-title":"Cell Death Differ"},{"key":"8992_CR97","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"V Del Gaizo Moore","year":"2013","unstructured":"Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202\u20135.","journal-title":"Cancer Lett"},{"key":"8992_CR98","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1101\/sqb.2016.81.030841","volume":"81","author":"DS Potter","year":"2016","unstructured":"Potter DS, Letai A. To prime, or not to prime: that is the question. Cold Spring Harb Symp Quant Biol. 2016;81:131\u201340.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"8992_CR99","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-4939-8861-7_4","volume":"1877","author":"C Fraser","year":"2019","unstructured":"Fraser C, Ryan J, Sarosiek K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. Methods Mol Biol. 2019;1877:61\u201376.","journal-title":"Methods Mol Biol"},{"key":"8992_CR100","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","volume":"185","author":"R Pan","year":"2022","unstructured":"Pan R, Ryan J, Pan D, Wucherpfennig KW, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185:1521\u201338.","journal-title":"Cell"},{"key":"8992_CR101","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/eji.200535387","volume":"36","author":"M von Geldern","year":"2006","unstructured":"von Geldern M, Simm B, Braun M, Weiss EH, Schendel DJ, Falk CS. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class. I Eur J Immunol. 2006;36:2347\u201358.","journal-title":"I Eur J Immunol"},{"key":"8992_CR102","doi-asserted-by":"publisher","first-page":"821","DOI":"10.17219\/acem\/35771","volume":"25","author":"S Martkamchan","year":"2016","unstructured":"Martkamchan S, Onlamoon N, Wang S, Pattanapanyasat K, Ammaranond P. The effects of anti-CD3\/CD28 coated beads and IL-2 on expanded T cell for immunotherapy. Adv Clin Exp Med. 2016;25:821\u201328.","journal-title":"Adv Clin Exp Med"},{"key":"8992_CR103","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1038\/sj.onc.1202615","volume":"18","author":"L Fang","year":"1999","unstructured":"Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, Aaronson SA. p21Waf1\/Cip1\/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene. 1999;18:2789\u201397.","journal-title":"Oncogene"},{"key":"8992_CR104","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/sj.onc.1202632","volume":"18","author":"Y Wang","year":"1999","unstructured":"Wang Y, Blandino G, Givol D. Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene. 1999;18:2643\u20139.","journal-title":"Oncogene"},{"key":"8992_CR105","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1158\/1541-7786.MCR-05-0121","volume":"3","author":"CM Aliouat-Denis","year":"2005","unstructured":"Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, van de Weyer I, et al. p53-independent regulation of p21Waf1\/Cip1 expression and senescence by Chk2. Mol Cancer Res. 2005;3:627\u201334.","journal-title":"Mol Cancer Res"},{"key":"8992_CR106","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41514-024-00168-y","volume":"10","author":"EA O\u2019Sullivan","year":"2024","unstructured":"O\u2019Sullivan EA, Wallis R, Mossa F, Bishop CL. The paradox of senescent-marker positive cancer cells: challenges and opportunities. npj Aging. 2024;10:41.","journal-title":"npj Aging"},{"key":"8992_CR107","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1038\/emboj.2012.122","volume":"31","author":"M Joaquin","year":"2012","unstructured":"Joaquin M, Gubern A, Gonz\u00e1lez-Nu\u00f1ez D, Josu\u00e9 Ruiz E, Ferreiro I, de Nadal E, et al. The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress. EMBO J. 2012;31:2952\u201364.","journal-title":"EMBO J"},{"key":"8992_CR108","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1080\/15384101.2019.1629792","volume":"18","author":"L Rodriguez Sawicki","year":"2019","unstructured":"Rodriguez Sawicki L, Garcia KA, Corsico B, Scaglia N. De novo lipogenesis at the mitotic exit is used for nuclear envelope reassembly\/expansion. Implications for combined chemotherapy. Cell Cycle. 2019;18:1646\u201359.","journal-title":"Cell Cycle"},{"key":"8992_CR109","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s42255-023-00747-5","volume":"5","author":"K Roh","year":"2023","unstructured":"Roh K, Noh J, Kim Y, Jang Y, Kim J, Choi H, et al. Lysosomal control of senescence and inflammation through cholesterol partitioning. Nat Metab. 2023;5:398\u2013413.","journal-title":"Nat Metab"},{"key":"8992_CR110","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41514-023-00128-y","volume":"10","author":"DV Ziegler","year":"2024","unstructured":"Ziegler DV, Czarnecka-Herok J, Vernier M, Scholtes C, Camprubi C, Huna A, et al. Cholesterol biosynthetic pathway induces cellular senescence through ERR\u03b1. npj Aging. 2024;10:5.","journal-title":"npj Aging"},{"key":"8992_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-025-00802-7","volume":"20","author":"S Wang","year":"2025","unstructured":"Wang S, Li B, Li J, Cai Z, Hugo C, Sun Y, et al. Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD. Mol Neurodegener. 2025;20:15.","journal-title":"Mol Neurodegener"},{"key":"8992_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37016-8","volume":"14","author":"LA Rowland","year":"2023","unstructured":"Rowland LA, Guilherme A, Henriques F, DiMarzio C, Munroe S, Wetoska N, et al. De novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics. Nat Commun. 2023;14:1362.","journal-title":"Nat Commun"},{"key":"8992_CR113","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s42255-021-00412-9","volume":"3","author":"W Chen","year":"2021","unstructured":"Chen W, Yu X, Wu Y, Tang J, Yu Q, Lv X, et al. The SESAME complex regulates cell senescence through the generation of acetyl-CoA. Nat Metab. 2021;3:983\u20131000.","journal-title":"Nat Metab"},{"key":"8992_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57334-3","volume":"16","author":"L Yang","year":"2025","unstructured":"Yang L, You J, Yang X, Jiao R, Xu J, Zhang Y, et al. ACSS2 drives senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation. Nat Commun. 2025;16:2071.","journal-title":"Nat Commun"},{"key":"8992_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1550-0","volume":"10","author":"J Fafi\u00e1n-Labora","year":"2019","unstructured":"Fafi\u00e1n-Labora J, Carpintero-Fern\u00e1ndez P, Jordan SJD, Shikh-Bahaei T, Abdullah SM, Mahenthiran M, et al. FASN activity is important for the initial stages of the induction of senescence. Cell Death Dis. 2019;10:318.","journal-title":"Cell Death Dis"},{"key":"8992_CR116","doi-asserted-by":"crossref","unstructured":"Marmisolle I, Mart\u00ednez J, Liu J, Mastrogiovanni M, Fergusson MM, Rovira II, et al. Reciprocal regulation of acetyl-CoA carboxylase 1 and senescence in human fibroblasts involves oxidant mediated p38 MAPK activation. Arch Biochem Biophys. 201;613:12\u201322.","DOI":"10.1016\/j.abb.2016.10.016"},{"key":"8992_CR117","doi-asserted-by":"publisher","first-page":"12481","DOI":"10.1073\/pnas.0605298103","volume":"103","author":"KD Taganov","year":"2006","unstructured":"Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006;103:12481\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8992_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00972-z","volume":"8","author":"M Mann","year":"2017","unstructured":"Mann M, Mehta A, Zhao JL, Lee K, Marinov GK, Garcia-Flores Y, et al. An NF-kappaB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Commun. 2017;8:851.","journal-title":"Nat Commun"},{"key":"8992_CR119","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","volume":"133","author":"JE Jaspers","year":"2023","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023;133:e166028.","journal-title":"J Clin Invest"},{"key":"8992_CR120","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s12094-025-03874-5","volume":"27","author":"LB Kwantwi","year":"2025","unstructured":"Kwantwi LB, Boafo JD, Egleh BE, Li M. CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches. Clin Transl Oncol. 2025;27:3285\u201392.","journal-title":"Clin Transl Oncol"},{"key":"8992_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109253","volume":"112","author":"T Liu","year":"2022","unstructured":"Liu T, Long X, Zhang Y, Jin J, Chen L, Liu A. IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy. Int Immunopharmacol. 2022;112:109253.","journal-title":"Int Immunopharmacol"},{"key":"8992_CR122","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202255884","volume":"24","author":"A Bocanegra","year":"2023","unstructured":"Bocanegra A, Fern\u00e1ndez-Hinojal G, Ajona D, Blanco E, Zuazo M, Garnica M, et al. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1\/PD-1 blockade in lung cancer. EMBO Rep. 2023;24:e55884.","journal-title":"EMBO Rep"},{"key":"8992_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100821","volume":"3","author":"R Uceda-Castro","year":"2022","unstructured":"Uceda-Castro R, Margarido AS, Cornet L, Vegna S, Hahn K, Song JY, et al. Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis. Cell Rep Med. 2022;3:100821.","journal-title":"Cell Rep Med"},{"key":"8992_CR124","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s43018-023-00712-x","volume":"5","author":"S Chaib","year":"2024","unstructured":"Chaib S, L\u00f3pez-Dom\u00ednguez JA, Lalinde-Guti\u00e9rrez M, Prats N, Marin I, Boix O, et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat Cancer. 2024;5:448\u201362.","journal-title":"Nat Cancer"},{"key":"8992_CR125","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.trecan.2024.11.010","volume":"11","author":"L Zhou","year":"2025","unstructured":"Zhou L, Ma B, Ruscetti M. Cellular senescence offers distinct immunological vulnerabilities in cancer. Trends Cancer. 2025;11:334\u201350.","journal-title":"Trends Cancer"},{"key":"8992_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99852-2","volume":"11","author":"M Poblocka","year":"2021","unstructured":"Poblocka M, Bassey AL, Smith VM, Falcicchio M, Manso AS, Althubiti M, et al. Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Sci Rep. 2021;11:20358.","journal-title":"Sci Rep"},{"key":"8992_CR127","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1042\/BST20231066","volume":"52","author":"V Dhokia","year":"2024","unstructured":"Dhokia V, Albati A, Smith H, Thomas G, Macip S. A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing. Biochem Soc Trans. 2024;52:1661\u201371.","journal-title":"Biochem Soc Trans"},{"key":"8992_CR128","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","volume":"4","author":"C Amor","year":"2024","unstructured":"Amor C, Fern\u00e1ndez-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging. 2024;4:336\u201349.","journal-title":"Nat Aging"},{"key":"8992_CR129","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583:127\u201332.","journal-title":"Nature"},{"key":"8992_CR130","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s43018-022-00462-2","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang L, Jin H, Jochems F, Wang S, Lieftink C, Martinez IM, et al. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nat Cancer. 2022;3:1284\u201399.","journal-title":"Nat Cancer"},{"key":"8992_CR131","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","volume":"29","author":"W Kelly","year":"2023","unstructured":"Kelly W, Diaz Duque AE, Michalek J, Konkel B, Caflisch L, Chen Y, et al. Phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma. Clin Cancer Res. 2023;29:2419\u201325.","journal-title":"Clin Cancer Res"},{"key":"8992_CR132","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","volume":"155","author":"R Loomba","year":"2018","unstructured":"Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155:1463\u201373.","journal-title":"Gastroenterology"},{"key":"8992_CR133","first-page":"1876","volume":"62","author":"RH te Poele","year":"2002","unstructured":"te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62:1876\u201383.","journal-title":"Cancer Res"},{"key":"8992_CR134","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20210079","volume":"41","author":"T Saleh","year":"2021","unstructured":"Saleh T, Alhesa A, Al-Balas M, Abuelaish O, Mansour A, Awad H, et al. Expression of therapy-induced senescence markers in breast cancer samples upon incomplete response to neoadjuvant chemotherapy. Biosci Rep. 2021;41:BSR20210079.","journal-title":"Biosci Rep"},{"key":"8992_CR135","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s43018-021-00183-y","volume":"2","author":"GB Ferraro","year":"2021","unstructured":"Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2:414\u201328.","journal-title":"Nat Cancer"},{"key":"8992_CR136","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41586-020-2969-2","volume":"588","author":"X Jin","year":"2020","unstructured":"Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, et al. A metastasis map of human cancer cell lines. Nature. 2020;588:331\u201336.","journal-title":"Nature"},{"key":"8992_CR137","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/14728222.2022.2077189","volume":"26","author":"JA Menendez","year":"2022","unstructured":"Menendez JA, Lupu R. Fatty acid synthase: a druggable driver of breast cancer brain metastasis. Expert Opin Ther Targets. 2022;26:427\u201344.","journal-title":"Expert Opin Ther Targets"},{"key":"8992_CR138","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357\u201360.","journal-title":"Nat Methods"},{"key":"8992_CR139","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290\u20135.","journal-title":"Nat Biotechnol"},{"key":"8992_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"8992_CR141","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47:W191\u201398.","journal-title":"Nucleic Acids Res"},{"key":"8992_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinforma. 2013;14:128.","journal-title":"BMC Bioinforma"},{"key":"8992_CR143","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006;38:500\u20131.","journal-title":"Nat Genet"},{"key":"8992_CR144","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"8992_CR145","doi-asserted-by":"publisher","first-page":"7515","DOI":"10.1021\/acs.analchem.9b05765","volume":"92","author":"P Bonini","year":"2020","unstructured":"Bonini P, Kind T, Tsugawa H, Barupal DK, Fiehn O. Retip: retention time prediction for compound annotation in untargeted metabolomics. Anal Chem. 2020;92:7515\u201322.","journal-title":"Anal Chem"},{"key":"8992_CR146","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/s41587-020-0531-2","volume":"38","author":"H Tsugawa","year":"2020","unstructured":"Tsugawa H, Ikeda K, Takahashi M, Satoh A, Mori Y, Uchino H, et al. A lipidome atlas in MS-DIAL 4. Nat Biotechnol. 2020;38:1159\u201363.","journal-title":"Nat Biotechnol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08992-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08992-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08992-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:02:33Z","timestamp":1788397353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08992-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":146,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8992"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08992-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. None of the experiments in this study involved the use of materials (i.e., human participants, human data, and\/or experiments on live vertebrates) that require ethical approval.","order":1,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors consented to the publication of this article. All data were in-house and no paper mills were used. To ensure integrity and accuracy, all authors agree to take responsibility for all aspects of the work.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All of the authors declare that they have no known competing financial interests or personal relationships that could appear to have influenced the work reported in this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"770"}}